ASLAN to Showcase Eblasakimab Phase 2 Data in Dupilumab-Resistant AD Patients at Virtual Event

ASLAN Pharmaceuticals, a biopharmaceutical firm with a focus on immunology, has reported promising results from a Phase 2 study on eblasakimab, a drug intended for atopic dermatitis (AD) patients. The company is set to present these findings at a virtual event, highlighting the potential of eblasakimab in patients who have not responded well to dupilumab.

The TREK-DX study, which is the first of its kind, involves a randomized, double-blind, placebo-controlled trial for AD patients previously treated with dupilumab. The study aims to evaluate the efficacy and safety of eblasakimab in these patients. The interim analysis revealed that eblasakimab could be a viable alternative for AD patients with limited treatment options, as it showed significant improvements in patient-reported outcomes and clinical assessments.

Dr. Carl Firth, CEO of ASLAN Pharmaceuticals, expressed excitement over the correlation between patient-reported itch scores and the investigator-assessed outcomes, such as the vIGA and EASI scores. The study's primary endpoint, the percent change in Eczema Area Severity Index (EASI) score, was statistically significant compared to placebo. Notably, a substantial percentage of patients treated with eblasakimab achieved EASI-90 and a vIGA score of 0 or 1, indicating significant skin improvement.

The KOL event featured discussions with medical experts on the growing market for AD patients seeking alternatives to dupilumab and the interim results from the TREK-DX study. The event also provided insights into the rapid onset of eblasakimab's effects and the consistent improvements observed in patients.

Eblasakimab is a monoclonal antibody that targets the IL-13 receptor subunit, which is crucial in allergic inflammatory diseases. Its unique mechanism can potentially improve upon existing treatments for allergic diseases by blocking the Type 2 receptor and preventing signaling through IL-4 and IL-13, key drivers of inflammation in AD.

ASLAN Pharmaceuticals is in the clinical stage of development and is committed to creating innovative treatments that can transform patient lives. The company has reported positive results from previous studies and is looking forward to the full dataset of the TREK-DX study later in the year.

The TREK-DX study's design includes a 16-week treatment period followed by an 8-week safety follow-up. The primary efficacy endpoint is the percentage change in EASI score, with secondary endpoints focusing on various validated measures of skin improvement and pruritus reduction.

ASLAN Pharmaceuticals is also developing farudodstat, an oral inhibitor for alopecia areata, with an interim readout expected in the third quarter of 2024. The company operates with teams in both the United States and Singapore and maintains an active presence on LinkedIn for further information.